Asset Details
Do you wish to reserve the book?
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Do you wish to request the book?
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
2019
Overview
Metabolic syndrome is characterized by a constellation of comorbidities that predispose individuals to an increased risk of developing cardiovascular pathologies as well as type 2 diabetes mellitus
1
. The gut microbiota is a new key contributor involved in the onset of obesity-related disorders
2
. In humans, studies have provided evidence for a negative correlation between
Akkermansia muciniphila
abundance and overweight, obesity, untreated type 2 diabetes mellitus or hypertension
3
–
8
. Since the administration of
A. muciniphila
has never been investigated in humans, we conducted a randomized, double-blind, placebo-controlled pilot study in overweight/obese insulin-resistant volunteers; 40 were enrolled and 32 completed the trial. The primary end points were safety, tolerability and metabolic parameters (that is, insulin resistance, circulating lipids, visceral adiposity and body mass). Secondary outcomes were gut barrier function (that is, plasma lipopolysaccharides) and gut microbiota composition. In this single-center study, we demonstrated that daily oral supplementation of 10
10
A. muciniphila
bacteria either live or pasteurized for three months was safe and well tolerated. Compared to placebo, pasteurized
A. muciniphila
improved insulin sensitivity (+28.62 ± 7.02%,
P
= 0.002), and reduced insulinemia (−34.08 ± 7.12%,
P
= 0.006) and plasma total cholesterol (−8.68 ± 2.38%,
P
= 0.02). Pasteurized
A. muciniphila
supplementation slightly decreased body weight (−2.27 ± 0.92 kg,
P
= 0.091) compared to the placebo group, and fat mass (−1.37 ± 0.82 kg,
P
= 0.092) and hip circumference (−2.63 ± 1.14 cm,
P
= 0.091) compared to baseline. After three months of supplementation,
A. muciniphila
reduced the levels of the relevant blood markers for liver dysfunction and inflammation while the overall gut microbiome structure was unaffected. In conclusion, this proof-of-concept study (clinical trial no.
NCT02637115
) shows that the intervention was safe and well tolerated and that supplementation with
A. muciniphila
improves several metabolic parameters.
Supplementation with
Akkermansia muciniphila
, a gut microbe previously associated with metabolic health in preclinical models, is safe and well tolerated in humans and may improve metabolic parameters in overweight and obese patients.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
